MedTrace Logo

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

NCT06933056 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-15

No results posted yet for this study

Summary

This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.

Conditions

  • Platelet Function and Reactivity Tests

Interventions

DRUG

Sotagliflozin (SOTA) followed by 3 drugs in a random order

400 mg/day SOTA Each drug will be given daily for 2 weeks.

DRUG

Aspirin followed by 3 drugs in a random order

81 mg/day Aspirin Each drug will be given daily for 2 weeks.

DRUG

Clopidogrel followed by 3 drugs in a random order

75 mg/day clopidogrel Each drug will be given daily for 2 weeks.

DRUG

Eliquis followed by 3 drugs in a random order

5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks.

Sponsors & Collaborators

Principal Investigators

  • Michael Holinstat, PhD · University of Michigan

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-02
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06933056 on ClinicalTrials.gov